EUVIMEDEUVIMED entdecken
Crossref

Beyond morphology: Toward integrated risk assessment in urinary cytology

Eva M Wojcik

Cancer Cytopathology · 2026-11 · 134 (11)

DOI: 10.1002/cncy.70164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cytopathology, online erschienen am 02.11.2026. Verfasst von Eva M Wojcik. Beteiligte Einrichtung: Loyola University Medical Center, Maywood, Illinois, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoma, Transitional Cell, Cytodiagnosis, Urinary Bladder Neoplasms. Die Arbeit nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urinary cytology remains the cornerstone of noninvasive detection and surveillance of urothelial carcinoma, particularly high‐grade disease. Despite the advances achieved through The Paris System, diagnostic challenges persist in the detection of low‐grade lesions and in the management of indeterminate cytologic findings. Two recent studies published in Cancer Cytopathology illustrate how ancillary biomarkers may address these limitations. Keratin 17 immunocytochemistry improved diagnostic performance when combined with cytology, particularly in morphologically subtle cases, whereas the methylation‐based Bladder EpiCheck assay enhanced risk stratification among patients with indeterminate cytology and negative cystoscopy. Together, these studies demonstrate that biomarkers provide the greatest clinical value when integrated with cytomorphologic assessment rather than used as standalone tests. Their findings support a future model of urinary cytology that combines morphologic expertise with immunocytochemical, molecular, and epigenetic biomarkers to improve urothelial carcinoma detection and individualized risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCarcinoma, Transitional CellCytodiagnosisUrinary Bladder NeoplasmsHumansRisk Assessment

Stichwörter der Autor:innen

Bladder EpiCheckThe Paris Systemkeratin 17urinary cytologyurine‐based diagnosticsurothelial carcinoma

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Loyola University Medical Center, Maywood, Illinois, USA.

Zitieren

APA

Wojcik, E. M. (2026). Beyond morphology: Toward integrated risk assessment in urinary cytology. Cancer Cytopathology, 134(11). https://doi.org/10.1002/cncy.70164

Vancouver

Wojcik EM. Beyond morphology: Toward integrated risk assessment in urinary cytology. Cancer Cytopathology. 2026;134(11). doi:10.1002/cncy.70164

BibTeX
@article{Wojcik2026,
  author = {Wojcik, Eva M},
  title = {Beyond morphology: Toward integrated risk assessment in urinary cytology},
  journal = {Cancer Cytopathology},
  year = {2026},
  volume = {134},
  number = {11},
  doi = {10.1002/cncy.70164}
}
Kostenlos starten →